Coronavirus (COVID-19) Related Guidance to Researchers
UMMS is implementing aggressive measures to mitigate the spread of COVID-19. After March 19, 2020, UMMS is restricting human subjects-related research visits to those that are essential to a subject’s wellbeing. Please see below for detailed guidance and relevant links.
3/25/2021
3/24/2021
11/25/2020
11/18/2020
11/12/2020
10/5/2020
8/13/2020
8/6/2020
7/20/2020
6/19/2020
6/15/2020
- UPDATED: Clinical Research Phase II June 2020
6/1/2020
5/14/2020
4/29/2020
4/28/2020
4/13/2020
4/3/2020
4/2/2020
3/31/2020
- HRP-803 Investigator Guidance - Documentation of Informed Consent- Temporary Exceptions for COVID19 Therapeutic Trials - STOP: Search above for the most recent version of this document.
3/24/2020
3/20/2020
3/18/2020
- Joint Guidance from UMCCTS & UMMS IRB COVID-19 Guidance for Investigators. Version 3: March 18, 2020
3/17/2020
- Joint Guidance from UMCCTS & UMMS IRB COVID-19 Guidance for Investigators. Version 2: March 17, 2020
3/16/2020
- Joint Guidance from UMCCTS & UMMS IRB COVID-19 Guidance for Investigators. Version 1: March 16, 2020
3/13/2020
3/12/2020
Additional Information/Resources:
- https://umassmed.edu/coronavirus
- https://www.umassmed.edu/research/sponsored-programs/covid-19-resources-for-researchers/
- https://www.umassmed.edu/ccts/irb/
- https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-087.html
- https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic